BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALX Oncology Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ALX Oncology Inc.'s drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07007559-3357@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Evorpacept: Phase 2 readout est. (NCT07007559)
DESCRIPTION:Evorpacept\, phase 2\, HER2-Positive Breast Cancer.\nStudy: ASP
 EN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemot
 herapy in Metastatic HER2-Positive Breast Cancer\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 evorpacept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07007559
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
